Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 33


VHL and kidney cancer.

Ohh M, Kaelin WG Jr.

Methods Mol Biol. 2003;222:167-83. Review. No abstract available.


The VHL protein recruits a novel KRAB-A domain protein to repress HIF-1alpha transcriptional activity.

Li Z, Wang D, Na X, Schoen SR, Messing EM, Wu G.

EMBO J. 2003 Apr 15;22(8):1857-67.


Multiple splice variants of the human HIF-3 alpha locus are targets of the von Hippel-Lindau E3 ubiquitin ligase complex.

Maynard MA, Qi H, Chung J, Lee EH, Kondo Y, Hara S, Conaway RC, Conaway JW, Ohh M.

J Biol Chem. 2003 Mar 28;278(13):11032-40. Epub 2003 Jan 21.


Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL.

Hergovich A, Lisztwan J, Barry R, Ballschmieter P, Krek W.

Nat Cell Biol. 2003 Jan;5(1):64-70.


Playing Tag with HIF: The VHL Story.

Leung SK, Ohh M.

J Biomed Biotechnol. 2002;2(3):131-135.


Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor.

Ivan M, Haberberger T, Gervasi DC, Michelson KS, G├╝nzler V, Kondo K, Yang H, Sorokina I, Conaway RC, Conaway JW, Kaelin WG Jr.

Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13459-64. Epub 2002 Sep 26.


The von Hippel-Lindau tumor suppressor stabilizes novel plant homeodomain protein Jade-1.

Zhou MI, Wang H, Ross JJ, Kuzmin I, Xu C, Cohen HT.

J Biol Chem. 2002 Oct 18;277(42):39887-98. Epub 2002 Aug 6.


An intact NEDD8 pathway is required for Cullin-dependent ubiquitylation in mammalian cells.

Ohh M, Kim WY, Moslehi JJ, Chen Y, Chau V, Read MA, Kaelin WG Jr.

EMBO Rep. 2002 Feb;3(2):177-82. Epub 2002 Jan 29.


Ubiquitination of a novel deubiquitinating enzyme requires direct binding to von Hippel-Lindau tumor suppressor protein.

Li Z, Na X, Wang D, Schoen SR, Messing EM, Wu G.

J Biol Chem. 2002 Feb 15;277(7):4656-62. Epub 2001 Dec 5.


C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation.

Epstein AC, Gleadle JM, McNeill LA, Hewitson KS, O'Rourke J, Mole DR, Mukherji M, Metzen E, Wilson MI, Dhanda A, Tian YM, Masson N, Hamilton DL, Jaakkola P, Barstead R, Hodgkin J, Maxwell PH, Pugh CW, Schofield CJ, Ratcliffe PJ.

Cell. 2001 Oct 5;107(1):43-54.


Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease.

Clifford SC, Cockman ME, Smallwood AC, Mole DR, Woodward ER, Maxwell PH, Ratcliffe PJ, Maher ER.

Hum Mol Genet. 2001 May 1;10(10):1029-38.


von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF.

Hoffman MA, Ohh M, Yang H, Klco JM, Ivan M, Kaelin WG Jr.

Hum Mol Genet. 2001 May 1;10(10):1019-27.


HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing.

Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, Salic A, Asara JM, Lane WS, Kaelin WG Jr.

Science. 2001 Apr 20;292(5516):464-8. Epub 2001 Apr 5.


Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation.

Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, von Kriegsheim A, Hebestreit HF, Mukherji M, Schofield CJ, Maxwell PH, Pugh CW, Ratcliffe PJ.

Science. 2001 Apr 20;292(5516):468-72. Epub 2001 Apr 5.


Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein.

Ohh M, Park CW, Ivan M, Hoffman MA, Kim TY, Huang LE, Pavletich N, Chau V, Kaelin WG.

Nat Cell Biol. 2000 Jul;2(7):423-7.


Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein.

Cockman ME, Masson N, Mole DR, Jaakkola P, Chang GW, Clifford SC, Maher ER, Pugh CW, Ratcliffe PJ, Maxwell PH.

J Biol Chem. 2000 Aug 18;275(33):25733-41.


Synthetic peptides define critical contacts between elongin C, elongin B, and the von Hippel-Lindau protein.

Ohh M, Takagi Y, Aso T, Stebbins CE, Pavletich NP, Zbar B, Conaway RC, Conaway JW, Kaelin WG Jr.

J Clin Invest. 1999 Dec;104(11):1583-91.


An important von Hippel-Lindau tumor suppressor domain mediates Sp1-binding and self-association.

Cohen HT, Zhou M, Welsh AM, Zarghamee S, Scholz H, Mukhopadhyay D, Kishida T, Zbar B, Knebelmann B, Sukhatme VP.

Biochem Biophys Res Commun. 1999 Dec 9;266(1):43-50.


Fibronectin fibrillogenesis: a paradigm for extracellular matrix assembly.

Schwarzbauer JE, Sechler JL.

Curr Opin Cell Biol. 1999 Oct;11(5):622-7. Review.


Supplemental Content

Support Center